Breaking: Leahy and Tillis introduce PTAB Reform Act

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Breaking: Leahy and Tillis introduce PTAB Reform Act

Leahy introduced the PTAB Reform Act

The new bill would codify Arthrex, scrap Fintiv and introduce sanctions for bad-faith IPR filers if enacted, among other things

US senators Patrick Leahy, John Cornyn and Thom Tillis introduced a new bill related to the Patent Trial and Appeal Board today, June 16.

The PTAB Reform Act, a 27-page document, will codify a transparent director review process, set out provisions to stop patent challengers from filing simultaneous or repeated inter partes reviews (IPR), and do away with Fintiv, among other things, if enacted.

On the matter of director review, included to satisfy the US Supreme Court’s ruling in Arthrex, the bill sets out that the USPTO director must make written decisions available to the public and set forth the reasons for review, modification, or setting aside of a PTAB edict.

The bill states that the USPTO can no longer use parallel litigation as the basis to deny an IPR.

The act also establishes new sanctions for those who file PTAB proceedings as part of an “abuse of process” including those petitioners who deliberately offer to delay or lose an IPR in exchange for consideration.

The sanctions include shifting costs, expert witness fees, or attorney fees, referring counsel to the Office of Enrollment and Discipline and, most strikingly, a bar preventing parties from filing post grant proceedings for one year.

An industry source at a pharma company, who reviewed the bill before it was released, said this wording may cause problems for challengers who discuss settlements, depending on how it’s applied.

“In almost every IPR we start, we offer settlement,” he explains. “Often, the patent owner will turn around and say ‘no way’ because they think our IPR has zero value, and then we subsequently prevail. But will the other side think we acted in bad faith and move for sanctions?”

Speaking on the bill’s release, Leahy said: “I’m proud to continue the work of ensuring that our patent system reinforces high-quality patents while protecting start-ups, small businesses, and American manufacturers from patents that do not represent true innovation.

“I have enjoyed working with senators Cornyn and Tillis to achieve that balance. This bill represents the Senate at its best – different sides coming together to achieve a thoughtful compromise that is greater than what either side could achieve alone.”

The road to PTAB Reform

The legislators revealed earlier this year that they intended to release a new PTAB bill that they hoped would attract broad bipartisan support in Congress.

Leahy, who’s set to retire from the Senate in November, introduced his own PTAB legislation – the Restoring the America Invents Act (RAIA) – along with Cornyn in September 2021, shortly after Managing IP broke the story of the bill’s imminent drop.

The RAIA failed to get enough support within the US legislature, however, spurring Leahy to turn to his Republican counterpart Tillis in the Senate Judiciary Intellectual Property Subcommittee. Leahy and Tillis are the chair and ranking member of said committee respectively.

Now that the senators have dropped their new bill, House representative Darrell Issa – the ranking member for the House Subcommittee on Courts, Intellectual Property and the Internet – will decide whether to introduce a companion piece of legislation in the House.

The new bill was reviewed and commented on by several stakeholder groups, including Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Innovation Organization (BIO) and the Alliance of Automobile Manufacturers.

Leahy’s staff had asked these organisations not to share any drafts given to them ahead of the final bill’s release.

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article